Vagus nerve stimulator surgery has been performed since the late 1990s, making it one of the longest-established neuromodulation therapies. The clinical question is not how the procedure works — that is a matter of surgical technique — but who benefits, how much, and what realistic expectations look like at 1, 5, and 10 years after implantation. This article focuses on outcomes, efficacy data, and the practical experience of living with a VNS device long-term.
Epilepsy Outcomes
The pivotal trials that led to FDA approval (E03 and E05) demonstrated that VNS reduced seizure frequency by 50% or more in approximately 25-30% of patients with drug-resistant partial-onset epilepsy at one year. This “50% responder rate” is the standard metric in epilepsy trials — it means a quarter to a third of patients experience a clinically meaningful reduction in seizure burden.
What makes VNS distinctive is that efficacy tends to improve with time. Long-term follow-up registries (extending to 5-10 years) show that the 50% responder rate rises to approximately 40-50% by year two and can exceed 60% at five years. The mechanism for this progressive improvement is not fully understood — it may involve gradual neuroplastic changes in brainstem and cortical circuits, or simply reflect optimised programming over successive clinic visits.
Complete seizure freedom is rare with VNS alone — approximately 5-8% of patients achieve it. VNS is best understood as an adjunctive therapy that reduces seizure burden rather than a cure. However, even partial reduction can be transformative: fewer seizures means fewer injuries, fewer emergency department visits, greater independence (including driving eligibility in some jurisdictions), and reduced medication burden for some patients.
Depression Outcomes
VNS for treatment-resistant depression (TRD) received FDA approval in 2005, though its evidence base is more nuanced. The pivotal acute study (D02) did not show statistically significant differences between active and sham stimulation at 10 weeks. However, longer-term observational data told a different story: at 12 months, response rates (defined as 50% or greater reduction in depression severity scores) reached approximately 27-34%, and remission rates reached 15-17%.
A large, long-term registry study (D21) comparing VNS plus treatment-as-usual versus treatment-as-usual alone in TRD patients found significantly better outcomes in the VNS group at 5 years, with cumulative response rates approximately 68% in the VNS group versus 41% in the comparison group. This suggests that VNS for depression, like VNS for epilepsy, is a therapy whose benefits accrue over time rather than appearing acutely.
The delayed onset of benefit is important for setting patient expectations. Patients who expect rapid improvement are likely to be disappointed; those who understand that VNS is a long-term adjunctive approach with gradual efficacy are better positioned to persist through the initial period of adjustment and optimisation.
Your local vagus nerve experts
Find a vagus nerve practitioner near you
Our directory lists 2,684 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.
Or browse by approach
- Polyvagal-informed therapy
- Somatic therapy
- HRV biofeedback
- Craniosacral therapy
- Breathwork
- Insomnia therapy (CBT-I)
The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.
Quality of Life Benefits
Beyond seizure counts and depression scores, VNS recipients consistently report improvements in quality of life metrics. These include better alertness and cognitive function (some epilepsy patients report improved attention, possibly related to reduced seizure-related cognitive disruption and noradrenergic modulation from locus coeruleus activation), improved mood (even in epilepsy patients without a comorbid depression diagnosis, mood improvements are commonly reported), and reduced medication side effects (when VNS allows dose reductions in antiepileptic drugs or antidepressants, patients often report improved energy, cognition, and overall wellbeing).
The handheld magnet feature provides a sense of agency for epilepsy patients who can use it to attempt seizure abortion during the aura phase. Whether the magnet reliably aborts seizures is debated — some patients report consistent benefit while others do not — but the psychological value of having an active intervention during a seizure should not be underestimated.
Who Benefits Most
Predicting which patients will respond to VNS remains imperfect. Some patterns have emerged from registry data: patients with generalised seizure types (particularly Lennox-Gastaut syndrome) may respond as well as those with focal seizures, despite VNS being formally approved only for partial-onset seizures. Younger patients may respond better than older patients. Patients whose seizures have a clear aura (suggesting a focal onset that may be susceptible to vagal afferent modulation) may benefit more from the magnet feature.
For depression, patients with moderate rather than the most severe treatment resistance may respond better. Patients who have shown some partial response to other treatments (rather than complete non-response to everything) appear to have a higher likelihood of VNS benefit, though the data on predictive factors remain limited.
Emerging Indications
Research is expanding VNS applications beyond epilepsy and depression. Implanted VNS is being investigated for heart failure (the INOVATE-HF trial was negative, but the ANTHEM-HF trial showed promising results with different stimulation parameters), stroke rehabilitation (the VNS-REHAB trial demonstrated that VNS paired with rehabilitative exercises significantly improved upper-limb motor recovery compared to rehabilitation alone — FDA cleared in 2021), cluster headache and migraine (though non-invasive VNS has largely overtaken implanted VNS for these indications), and rheumatoid arthritis (SetPoint Medical’s bioelectronic device for inflammatory conditions received FDA approval in July 2025, representing a new category of implanted VNS for autoimmune disease).
The SetPoint Medical approval is particularly significant because it validates the concept of “bioelectronic medicine” — using targeted vagal stimulation to modulate the cholinergic anti-inflammatory pathway as a treatment for inflammatory disease. This opens a therapeutic category beyond neurology and psychiatry.
Making the Decision
The decision to proceed with VNS implantation should involve a realistic assessment of expected benefit, timeline, and alternatives. For epilepsy patients, the key question is whether the modest but real chance of meaningful seizure reduction (approximately 1 in 3 at one year, improving to 1 in 2 at five years) justifies surgery. For depression patients, the question is whether the slower and less certain trajectory of benefit is acceptable given the severity of treatment resistance and the impact of ongoing depression.
VNS does not replace medications — most patients continue their existing drug regimens. It does not replace epilepsy surgery in patients who are good surgical candidates (resective surgery has higher seizure-freedom rates when a clear focal lesion is identified). It is an additional tool for patients who have exhausted or are not candidates for other approaches.
VNS surgery outcomes illustrate how stimulating the vagus nerve can produce real clinical benefit — gradually, modestly, but measurably. For the broader science of how this nerve influences every system in your body and what the evidence says about supporting it, get the Vagus Nerve & Me eBook.




